Healthcare Stocks

Choice's forecast indicates significant earnings growth for Park Medi World, expecting revenue to rise from ₹16.8 billion in FY26 to ₹39.4 billion by FY29, with stable EBITDA margins of 26.5%. The brokerage maintains a 'BUY' rating and sets a target price of ₹350.

India's benchmark indices fell on May 11, with Nifty 50 down 1.04%. The rupee weakened amid rising oil prices. While large caps struggled, mid and small-cap stocks showed strong performance, signaling a potential shift in market dynamics.

Park Medi shares have surged 70% in 2026 so far, outperforming the market and pushing market cap over ₹10,000 crore. Analysts expect continued momentum due to the scalable healthcare model and strong demand.

Ventura Securities has given Park Medi World a ‘Buy’ rating with a target price of ₹284, expecting a 38.4% upside. The brokerage highlights PMWL's efficient operating model and growth potential in India's healthcare sector, predicting significant revenue increases over the next few years.

Avendus Spark Institutional Equities has initiated coverage on Dr. Agarwal’s Health Care, giving it a 'buy' rating and a target price of ₹495. The company is well-positioned in the eye care market, anticipating strong growth driven by acquisitions and surgical revenues.

The Indian stock market closed lower, with Nifty 50 down 156 points and Sensex falling 466 points due to selling pressure and global uncertainty. Despite positive earnings forecasts, investor caution persisted, impacting sectors like healthcare and financial services.

UnitedHealth expects growth in 2026 as CEO Stephen Hemsley steers the company to recovery. Medical costs remain high, but in line with company expectations, while quarterly revenue at its Optum health services unit was flat.